Monte Rosa Therapeutics, Inc. financial data

Symbol
GLUE on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
17 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 629% % 61%
Debt-to-equity 63% % -9.9%
Return On Equity -15% % 58%
Return On Assets -9.3% % 56%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 80,015,667 shares 30%
Common Stock, Shares, Outstanding 65,543,723 shares 6.6%
Entity Public Float $212,000,000 USD 6.5%
Common Stock, Value, Issued $7,000 USD 17%
Weighted Average Number of Shares Outstanding, Basic 83,071,185 shares 12%
Weighted Average Number of Shares Outstanding, Diluted 83,071,185 shares 12%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $141,500,000 USD 16%
General and Administrative Expense $36,380,000 USD 3.4%
Operating Income (Loss) $54,208,000 USD 33%
Nonoperating Income (Expense) $14,485,000 USD 32%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $39,723,000 USD 43%
Income Tax Expense (Benefit) $1,097,000 USD -143%
Net Income (Loss) Attributable to Parent $38,626,000 USD 47%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $129,883,000 USD -42%
Cash, Cash Equivalents, and Short-term Investments $377,100,000 USD
Accounts Receivable, after Allowance for Credit Loss, Current $9,000,000 USD
Assets, Current $393,185,000 USD 4.2%
Property, Plant and Equipment, Net $25,986,000 USD -12%
Operating Lease, Right-of-Use Asset $24,386,000 USD -9.1%
Other Assets, Noncurrent $148,000 USD 29%
Assets $448,659,000 USD 2.3%
Accounts Payable, Current $3,550,000 USD -79%
Employee-related Liabilities, Current $9,998,000 USD 22%
Accrued Liabilities, Current $26,694,000 USD 42%
Liabilities, Current $64,212,000 USD -59%
Operating Lease, Liability, Noncurrent $34,794,000 USD -11%
Liabilities $215,603,000 USD -0.09%
Accumulated Other Comprehensive Income (Loss), Net of Tax $3,827,000 USD -14%
Retained Earnings (Accumulated Deficit) $477,214,000 USD -8.8%
Stockholders' Equity Attributable to Parent $233,056,000 USD 4.5%
Liabilities and Equity $448,659,000 USD 2.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $45,492,000 USD -19%
Net Cash Provided by (Used in) Financing Activities $246,000 USD
Net Cash Provided by (Used in) Investing Activities $100,229,000 USD -1117%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 65,543,723 shares 6.6%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $145,707,000 USD -419%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $134,837,000 USD -41%
Deferred Tax Assets, Valuation Allowance $73,626,000 USD 2%
Deferred Tax Assets, Gross $83,406,000 USD 0.35%
Depreciation $8,356,000 USD 2.9%
Payments to Acquire Property, Plant, and Equipment $1,587,000 USD 15%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $39,097,000 USD 47%
Property, Plant and Equipment, Gross $53,599,000 USD 7.5%
Operating Lease, Liability, Current $4,397,000 USD 18%
Operating Lease, Weighted Average Discount Rate, Percent 0.099 pure 1%
Deferred Tax Assets, Operating Loss Carryforwards $52,865,000 USD 5.7%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Amortization of Intangible Assets $2,500,000 USD 19%
Deferred Tax Assets, Net of Valuation Allowance $9,780,000 USD -11%
Share-based Payment Arrangement, Expense $18,865,000 USD 4.1%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%